Pharmacom Labs Oxandrolonos is presented in a 100 tablet box with 2 blister packs of 50 tablets each. Each tablet reportedly contains 10 milligrams of oxandrolone according to the label and packaging. Samples of this product were purchased from a North American-based authorized distributor between the dates of June 1, 2015 and June 30, 2015. The samples were forwarded and received by the analytical laboratory SIMEC AG for HPLC-UV testing on July 20, 2015. The quantitative dosage testing report was completed on August 10, 2015. The product was identified with an expiration date of October 15, 2018 and a batch number of MBMN1. There was no verification code printed on the box.
Anabolic steroids are synthetic versions of hormones that human body produces naturally. Their main role is to assure increased physical performance in all sports and athletic pursuits. Steroidal compounds enhance stamina, strength, weight and size of muscles and may improve the energy levels during physical training. Oral and injectable steroids posses the ability to increase athletic performance, have a positive effect on red blood cells production and bones density. The steroids are used in accordance with requirement and needs of any athlete individually. There are special compounds which are not suitable for women and a series of anti-estrogen products which main role is to counter the eventual side effects of steroids use and to restore natural testosterone levels of the human body. These compounds nowadays became an important part of muscle building process among professional athletes and bodybuilders, as well as regular people, males and females that have the goal to become more attractive and exhibit good looks. Follow us on Twitter | Steroids Store - Pinterest .
COUMADIN can cause fetal harm when administered to a pregnant woman. While COUMADIN is contraindicated during pregnancy, the potential benefits of using COUMADIN may outweigh the risks for pregnant women with mechanical heart valves at high risk of thromboembolism . In those individual situations, the decision to initiate or continue COUMADIN should be reviewed with the patient, taking into consideration the specific risks and benefits pertaining to the individual patient’s medical situation, as well as the most current medical guidelines. COUMADIN exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage , and an increased risk of spontaneous abortion and fetal mortality. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use In Specific Populations ].